Breaking News, Collaborations & Alliances

Altea Enters Exenatide Patch Pact with Amylin and Lilly

Altea Therapeutics has entered into an agreement with Eli Lilly and Co. and Amylin Pharmaceuticals to develop and commercialize a daily transdermal patch delivering sustained levels of Byetta (exenatide) using Altea's PassPort Transdermal Delivery System.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Altea Therapeutics has entered into an agreement with Eli Lilly and Co. and Amylin Pharmaceuticals to develop and commercialize a daily transdermal patch delivering sustained levels of Byetta (exenatide) using Altea’s PassPort Transdermal Delivery System. The three companies recently completed an initial Phase I study of the exenatide transdermal patch in people with type 2 diabetes. The exenatide transdermal patch is an investigational product designed to be applied once a day to provi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters